SLC5A2 and chronic kidney disease: In this era of “big data,” including use of very large databases from health records, registries, and multicenter research studies, there is an opportunity to learn more about for both characterization and understanding of CKD and HF, as well as for optimizing the use of the pillars of therapy for HF: beta-blockers, ACE inhibitors, angiotensin II receptor inhibitors, angiotensin receptor-neprilysin inhibitors, MRAs, and SGLT2 inhibitors.